AU Patent

AU2017241837B2 — Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

Assigned to Signal Pharmaceuticals LLC · Expires 2021-07-22 · 5y expired

What this patent protects

Provided herein are methods for treating or preventing a cancer, including solid tumors and hematological cancers, comprising administering an effective amount of aminopurine compounds of formula (I), and compositions comprising an effective amount of such compounds.

USPTO Abstract

Provided herein are methods for treating or preventing a cancer, including solid tumors and hematological cancers, comprising administering an effective amount of aminopurine compounds of formula (I), and compositions comprising an effective amount of such compounds.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017241837B2
Jurisdiction
AU
Classification
—
Expires
2021-07-22
Drug substance claim
No
Drug product claim
No
Assignee
Signal Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.